 |
|
|
|
|
New Chemotherapy Combo Holds Promise for Lung Cancer
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The findings are published in the Aug. 15 issue of Clinical Cancer Research.
About 28 percent of patients responded to the treatment. They lived for an average of 15 months and made it an average of 4.9 months without getting worse.
The researchers reported that the patients suffered less severe side effects than would be expected if they'd taken the usual platinum-based chemotherapy.
Text Continues Below
According to the researchers, studies of the existing platinum treatment suggest that patients who take it live for an average of seven to 14 months.
The next step would be to directly compare the new chemotherapy regimen to the existing platinum treatment by randomly assigning patients to one or the other.
More information
Learn more about non-small cell lung cancer from the American Cancer Society.
Page: << Prev | 1 | 2
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 8/12/2008
|
|
SOURCES: Norman Edelman, M.D., chief medical officer, American Lung Association; Isamu Okamoto, M.D., Ph.D., associate professor, Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan; Aug. 15, 2008, Clinical Cancer Research
|
.gif)
